Patent Infringement Claims Clarified In Festo Ruling
Executive Summary
A federal appeals court decision in the Festo case further clarifies the circumstances under which pharmaceutical patent holders can assert infringement claims under the doctrine of equivalents
You may also be interested in...
Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent
Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent
Wellbutrin SR Patent Cases: Did GSK Surrender Claims To Excipients?
GlaxoSmithKline's patent infringement cases against Impax and Excel regarding Wellbutrin SR and Zyban appear to hinge on whether excipients used by the generic firms were "foreseeable.